Please select the option that best describes you:

For patients on a bone-modifying agent for osteoporosis/severe osteopenia in the context of adjuvant AI therapy, how do you manage the bone-modifying agent once their AI course is complete?  



Answer from: Medical Oncologist at Academic Institution
Sign in or Register to read more